There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels ≥10.1 mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat-to-target strategy.

Background & Aims-Experimental evidence indicates that proton pump inhibitors (PPI), nonsteroidal anti inflammatory drugs (NSAID)/aspirin and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE.

Our findings may be useful for surgical planning in an era of patient-specific care. The findings suggest that surgeons should aim for a patient-specific lumbar shape rather than simple global lordosis matched to the PI.